1.Preliminary study on the occurrence of pten and PIK3CA gene mutations in endometrial cancer among Malaysian women
Subramaniam KS ; Wong MS ; Woo Yl ; Mat Adenan NA ; Mohamed Z ; Chung
Journal of University of Malaya Medical Centre 2013;16(1):1-5
Genetic mutations in endometrial cancer (EC) have been extensively studied in the Western population but
not much in Asian cohorts. This study has demonstrated that PTEN and PIK3CA mutations are commonly
found in EC among Malaysian women. Following RNA extraction from 20 cancerous and 18 non-cancerous
tissues, the presence of mutations in 9 exons of PTEN and 3 exons of PIK3CA genes were detected using realtime
PCR, accompanied by High Resolution Melt (HRM) analysis. Sequencing confirmed specificity of each
PCR product. The mutations for both genes were detected in the samples with varying frequencies. Notably,
all samples expressed mutation of PTEN at exon 7 but none in exon 4. Further analysis demonstrated that
strong concurrent mutations occurred between exons 7 of PTEN with exon 20 region 1 of PIK3CA gene (90%).
Our data showed mutations are present in EC and not the non-cancerous tissues. Larger samples are being
collected to validate this observation.
Uterine Neoplasms
2.A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Wen Jun TIEW ; Vivien Lx WONG ; Vern Hsen TAN ; Yong Chuan TAN ; Elena Ms LEE
Annals of the Academy of Medicine, Singapore 2020;49(11):838-847
INTRODUCTION:
Non-vitamin K oral anticoagulants (NOACs) were shown to have better outcomes than warfarin for non-valvular atrial fibrillation (NVAF). Given limited local real-world data, this study aims to evaluate the safety and efficacy of NOACs versus warfarin for NVAF in Singapore.
METHODS:
This single-centre retrospective cohort study included 439 patients ≥ 21 years old that were newly prescribed with oral anticoagulants (OACs) for NVAF in 2015. Follow-ups for patients upon OAC initiation lasted either for 2 years or until the occurrence of bleeding or thromboembolism event or death (whichever was earlier). Primary endpoints included major bleeding and stroke, while secondary endpoints included overall bleeding and thromboembolic events. Time-to-events was evaluated via Kaplan-Meier survival analysis. Data on time in therapeutic range (TTR) and compliance were analysed.
RESULTS:
Patients were assigned to 4 groups: warfarin (157, 35.8%), rivaroxaban (154, 35.1%), apixaban (98, 22.3%) and dabigatran (30, 6.8%). With a mean age of 70.8 (±10.8) years old, the population were predominantly males (56.5%) and comprised Chinese (73.8%), Malays (18.7%) and others (7.5%). The rates of stroke per year were 0.7%, 1.7%, 2.2% and 0% for warfarin, rivaroxaban, apixaban and dabigatran, respectively (
CONCLUSION
NOACs were associated with similar stroke and major bleeding rates as warfarin for NVAF.
3.COVID-19 in Singapore and Malaysia: Rising to the Challenges of Orthopaedic Practice in an Evolving Pandemic
Tay K, FRSC Ed Orth ; Kamarul T, MS Orth ; Lok WY, FRCS Ed Orth ; Mansor M, M Anaes ; Li X, MRCOG ; Wong J, FANZCA ; Saw A, FRCS Ed
Malaysian Orthopaedic Journal 2020;14(No.2):7-16
With the increasing number of COVID-19 cases and related deaths worldwide, we decided to share the development of this condition in Singapore and Malaysia. First few cases were diagnosed in the two countries at the end of January 2020, and the numbers have surged to thousands by end of March 2020. We will focus on strategies adopted by the government and also the Orthopaedic community of the two countries up till the beginning of April 2020. We hope that by sharing of relevant information and knowledge on how we are managing the COVID-19 condition, we can help other communities, and health care workers to more effectively overcome this pandemic.